The QKI-PLP pathway controls SIRT2 abundance in CNS myelin

GLIA

Volumn 60, Issue 1, 2012, Pages 69-82

  Zhu, H ^a   Zhao, L ^b   Wang, E ^a   Dimova, N ^a   Liu, G ^b   Feng, Y ^b   Cambi, F ^a  

^a UNIVERSITY OF KENTUCKY   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Development; Myelin; Oligodendrocytes; PLP; Quaking; Sirtuin2

Indexed keywords

MESSENGER RNA; MYELIN; PROTEOLIPID PROTEIN; QKI PROTEIN; RNA BINDING PROTEIN; SIRTUIN 2; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN LEVEL; CELL FUNCTION; CENTRAL NERVOUS SYSTEM; CONTROLLED STUDY; CYTOPLASM; DOWN REGULATION; MOUSE; MYELIN SHEATH; NONHUMAN; OLIGODENDROGLIA; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY MECHANISM;

AGE FACTORS; ANIMALS; ANIMALS, NEWBORN; BRAIN; CELL DIFFERENTIATION; FLOW CYTOMETRY; GENE EXPRESSION REGULATION, DEVELOPMENTAL; GREEN FLUORESCENT PROTEINS; MICE; MICE, INBRED C57BL; MICE, QUAKING; MICE, TRANSGENIC; MUTATION; MYELIN PROTEOLIPID PROTEIN; MYELIN SHEATH; OLIGODENDROGLIA; RECEPTORS, ATRIAL NATRIURETIC FACTOR; RNA, MESSENGER; RNA-BINDING PROTEINS; SIGNAL TRANSDUCTION; SIRTUIN 2;

EID: 81155155536     PISSN: 08941491     EISSN: 10981136     Source Type: Journal    
DOI: 10.1002/glia.21248     Document Type: Article

References (43)

1. Aberg K, Saetre P, Jareborg N, Jazin E. 2006a. Human QKI, a potential regulator of mRNA expression of human oligodendrocyte-related genes involved in schizophrenia. Proc Natl Acad Sci USA 103: 7482-7487.
2. Aberg K, Saetre P, Lindholm E, Ekholm B, Pettersson U, Adolfsson R, Jazin E. 2006b. Human QKI, a new candidate gene for schizophrenia involved in myelination. Am J Med Genet B Neuropsychiatr Genet 141: 84-90.
3. Bargagna-Mohan P, Paranthan RR, Hamza A, Dimova N, Trucchi B, Srinivasan C, Elliott GI, Zhan CG, Lau DL, Zhu H, Kasahara K, Inagaki M, Cambi F, Mohan R. 2010. Withaferin A targets intermediate filaments glial fibrillary acidic protein and vimentin in a model of retinal gliosis. J Biol Chem 285: 7657-7669.
4. Barrie JA, Montague P, Karim S, Kirkham D, Nave KA, Anderson TJ, Griffiths IR, McLaughlin M. 2010. Modulation of rumpshaker phenotype with wild-type PLP/DM20 suggests several pathogenic mechanisms. J Neurosci Res 88: 2135-2145.
5. Bockbrader K, Feng Y. 2008. Essential function, sophisticated regulation and pathological impact of the selective RNA-binding protein QKI in CNS myelin development. Future Neurol 3: 655-668.
6. Chen Y, Tian D, Ku L, Osterhout DJ, Feng Y. 2007. The selective RNA-binding protein quaking I (QKI) is necessary and sufficient for promoting oligodendroglia differentiation. J Biol Chem 282: 23553-23560.
7. Ebersole TA, Chen Q, Justice MJ, Artzt K. 1996. The quaking gene product necessary in embryogenesis and myelination combines features of RNA binding and signal transduction proteins. Nat Genet 12: 260-265.
8. Edgar JM, McLaughlin M, Yool D, Zhang SC, Fowler JH, Montague P, Barrie JA, McCulloch MC, Duncan ID, Garbern J, Nave KA, Griffiths IR. 2004. Oligodendroglial modulation of fast axonal transport in a mouse model of hereditary spastic paraplegia. J Cell Biol 166: 121-131.
9. Galarneau A, Richard S. 2005. Target RNA motif and target mRNAs of the Quaking STAR protein. Nat Struct Mol Biol 12: 691-698.
10. Garbern J, Shy M, Krajewski K, Kamholz J, Hobson G, Cambi F. 2001. Evidence for neuroaxonal injury in patients with proteolipid gene mutations. Neurology 57: 1938-1939.
11. Gudz TI, Schneider TE, Haas TA, Macklin WB. 2002. Myelin proteolipid protein forms a complex with integrins and may participate in integrin receptor signaling in oligodendrocytes. J Neurosci 22: 7398-7407.
12. Hafner M, Landthaler M, Burger L, Khorshid M, Hausser J, Berninger P, Rothballer A, Ascano MJr, Jungkamp AC, Munschauer M, et al. 2010. Transcriptome-wide identification of RNA-binding protein and microRNA target sites by PAR-CLIP. Cell 141: 129-141.
13. Hardy RJ, Loushin CL, Friedrich VLJr, Chen Q, Ebersole TA, Lazzarini RA, Artzt K. 1996. Neural cell type-specific expression of QKI proteins is altered in quakingviable mutant mice. J Neurosci 16: 7941-7949.
14. Haroutunian V, Katsel P, Dracheva S, Davis KL. 2006. The human homolog of the QKI gene affected in the severe dysmyelination "quaking" mouse phenotype: Downregulated in multiple brain regions in schizophrenia. Am J Psychiatry 163: 1834-1837.
15. Hobson GM, Huang Z, Sperle K, Stabley DL, Marks HG, Cambi F. 2002. A PLP splicing abnormality is associated with an unusual presentation of PMD. Ann Neurol 52: 477-488.
16. Huang Z, Tang XM, Cambi F. 2002. Down-regulation of the retinoblastoma protein (rb) is associated with rat oligodendrocyte differentiation. Mol Cell Neurosci 19: 250-262.
17. Klugmann M, Schwab MH, Pühlhofer A, Schneider A, Zimmermann F, Griffiths IR, Nave K-A. 1997. Assembly of CNS myelin in the absence of proteolipid protein. Neuron 18: 59-70.
18. Larocque D, Galarneau A, Liu HN, Scott M, Almazan G, Richard S. 2005. Protection of p27(Kip1) mRNA by quaking RNA binding proteins promotes oligodendrocyte differentiation. Nat Neurosci 8: 27-33.
19. Larocque D, Richard S. 2005. QUAKING KH domain proteins as regulators of glial cell fate and myelination. RNA Biol 2: 37-40.
20. Li W, Zhang B, Tang J, Cao Q, Wu Y, Wu C, Guo J, Ling EA, Liang F. 2007. Sirtuin 2, a mammalian homolog of yeast silent information regulator-2 longevity regulator, is an oligodendroglial protein that decelerates cell differentiation through deacetylating alpha-tubulin. J Neurosci 27: 2606-2616.
21. Li Z, Zhang Y, Li D, Feng Y. 2000. Destabilization and mislocalization of myelin basic protein mRNAs in quaking dysmyelination lacking the QKI RNA-binding proteins. J Neurosci 20: 4944-4953.
22. Lu Z, Ku L, Chen Y, Feng Y. 2005. Developmental abnormalities of myelin basic protein expression in fyn knock-out brain reveal a role of Fyn in posttranscriptional regulation. J Biol Chem 280: 389-395.
23. Lu Z, Zhang Y, Ku L, Wang H, Ahmadian A, Feng Y. 2003. The quakingviable mutation affects qkI mRNA expression specifically in myelin-producing cells of the nervous system. Nucleic Acids Res 31: 4616-4624.
24. Macklin WB, Campagnoni CW, Deininger PL, Gardinier MV. 1987. Structure and expression of the mouse myelin proteolipid protein gene. J Neurosci Res 18: 383-394.
25. Marin-Husstege M, Muggironi M, Liu A, Casaccia-Bonnefil P. 2002. Histone deacetylase activity is necessary for oligodendrocyte lineage progression. J Neurosci 22: 10333-10345.
26. Michan S, Sinclair D. 2007. Sirtuins in mammals: Insights into their biological function. Biochem J 404: 1-13.
27. Nahhas F, Dryden SC, Abrams J, Tainsky MA. 2007. Mutations inSIRT2 deacetylase which regulate enzymatic activity but not itsinteraction with HDAC6 and tubulin. Mol Cell Biochem 303: 221-230.
28. Roth AD, Ivanova A, Colman DR. 2006. New observations on the compact myelin proteome. Neuron Glia Biol 2: 15-21.
29. Saugier-Veber P, Munnich A, Bonneau D, Rozet JM, Le Merrer M, Gil R, Boespflug-Tanguy O. 1994. X-linked spastic paraplegia and Pelizaeus-Merzbacher disease are allelic disorders at the proteolipid protein locus. Nat Genet 6: 257-262.
30. Schneeman TA, Bruno ME, Schjerven H, Johansen FE, Chady L, Kaetzel CS. 2005. Regulation of the polymeric Ig receptor by signaling through TLRs 3 and 4: Linking innate and adaptive immune responses. J Immunol 175: 376-384.
31. Sinclair D. 2005. Sirtuins for healthy neurons. Nat Genet 37: 339-340.
32. Southwood CM, Peppi M, Dryden S, Tainsky MA, Gow A. 2007. Microtubule deacetylases, SirT2 and HDAC6, in the nervous system. Neurochem Res 32: 187-195.
33. Sperber BR, Boyle-Walsh EA, Engleka MJ, Gadue P, Peterson AC, Stein PL, Scherer SS, McMorris FA. 2001. A unique role for Fyn in CNS myelination. J Neurosci 21: 2039-2047.
34. Stecca B, Southwood CM, Gragerov A, Kelley KA, Friedrich VLJr, Gow A. 2000. The evolution of lipophilin genes from invertebrates to tetrapods: DM-20 cannot replace proteolipid protein in CNS myelin. J Neurosci 20: 4002-4010.
35. Tkachev D, Mimmack ML, Huffaker SJ, Ryan M, Bahn S. 2007. Further evidence for altered myelin biosynthesis and glutamatergic dysfunction in schizophrenia. Int J Neuropsychopharmacol 10: 557-563.
36. Tkachev D, Mimmack ML, Ryan MM, Wayland M, Freeman T, Jones PB, Starkey M, Webster MJ, Yolken RH, Bahn S. 2003. Oligodendrocyte dysfunction in schizophrenia and bipolar disorder. Lancet 362: 798-805.
37. Wang E, Dimova N, Cambi F. 2007. PLP/DM20 ratio is regulated by hnRNPH and F and a novel G-rich enhancer in oligodendrocytes. Nucleic Acids Res 35: 4164-4178.
38. Wang E, Dimova N, Sperle K, Huang Z, Lock L, McCulloch MC, Edgar JM, Hobson GM, Cambi F. 2008. Deletion of a splicing enhancer disrupts PLP1/DM20 ratio and myelin stability. Exp Neurol 214: 322-330.
39. Werner HB, Kuhlmann K, Shen S, Uecker M, Schardt A, Dimova K, Orfaniotou F, Dhaunchak A, Brinkmann BG, Mobius W, et al. 2007. Proteolipid protein is required for transport of sirtuin 2 into CNS myelin. J Neurosci 27: 7717-7730.
40. Wu JI, Reed RB, Grabowski PJ, Artzt K. 2002. Function of quaking in myelination: regulation of alternative splicing. Proc Natl Acad Sci USA 99: 4233-4238.
41. Yuan X, Chittajallu R, Belachew S, Anderson S, McBain CJ, Gallo V. 2002. Expression of the green fluorescent protein in the oligodendrocyte lineage: A transgenic mouse for developmental and physiological studies. J Neurosci Res 70: 529-545.
42. Zhao L, Mandler MD, Yi H, Feng Y. 2010. Quaking I controls a unique cytoplasmic pathway that regulates alternative splicing of myelin-associated glycoprotein. Proc Natl Acad Sci USA 107: 19061-19066.
43. Zhao L, Tian D, Xia M, Macklin WB, Feng Y. 2006. Rescuing qkV dysmyelination by a single isoform of the selective RNA-binding protein QKI. J Neurosci 26: 11278-11286.